Other · developed by Damora Therapeutics
DMR-001 is an agent studied in myeloproliferative neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07849231 | Phase 1 | Myeloproliferative Neoplasms (MPNs) | Recruiting | DMRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myeloproliferative Neoplasms (MPNs)
Updated Nov 15, 2026. Something wrong or missing? Report it on the DMRA page.
See DMRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
DMRA catalysts and pipeline →